Akoya Biosciences (AKYA) announced an exclusive global license agreement to develop and commercialize NeraCare’s Immunoprint test on Akoya’s multiplexed immunofluorescent platform. Building on the research collaboration between the companies announced earlier this year, the license agreement grants Akoya the exclusive right to develop, market and commercialize the test for clinical research, diagnostic development or, following regulatory approval, patient clinical testing as both a laboratory test or a distributable diagnostic on Akoya’s PhenoImager HT platform.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Akoya Biosciences price target lowered to $3 from $4 at Piper Sandler
- Morgan Stanley, Comerica upgraded: Wall Street’s top analyst calls
- Akoya Biosciences downgraded to Hold from Buy at Craig-Hallum
- Akoya Biosciences price target lowered to $3.50 from $6 at Canaccord
- Akoya Biosciences Reports Q3 2024 Financial Results